HIMS
New legal drama, same soap opera
Hims & Hers is back in the headlines, and not for a shiny new product or a cute wellness ad. The company’s CEO is pushing back against an FTC suit, basically telling the market: “We’re not the bad guy here, we’re the disruptor.”
That’s a nice line for a podcast clip. It’s less fun if you’re a shareholder trying to figure out whether the company can grow without constantly tripping over court papers.
Why investors should care
This matters because legal noise can turn into very real business drag. The stock already has a pile of recent legal headlines around it, so another round of FTC-related sparring keeps the overhang alive.
For investors, the question isn’t just whether Hims can win the PR battle. It’s whether the company can keep scaling while regulators, plaintiffs, and the Street all crowd the stage at once.
Big picture
Hims has spent a lot of time selling itself as a scrappy healthcare rebel. That vibe works great in marketing. In a courtroom? Less so. The bigger takeaway: the company may still be growing, but the legal bill is starting to look like part of the business model.